All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 67 points (-0.4%) at 18,405 as of Thursday, July 28, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,296 issues advancing vs. 1,538 declining with 200 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.2%. Top gainers within the sector include

Molina Healthcare

(

MOH

), up 16.9%,

AstraZeneca

(

AZN

), up 7.2%,

Varian Medical Systems

(

VAR

), up 5.8%,

Quintiles Transnational Holdings

(

Q

), up 3.4% and

Centene

(

CNC

), up 3.1%. On the negative front, top decliners within the sector include

Mednax

(

MD

), down 7.5%,

Alkermes

(

ALKS

), down 7.4%,

Grifols

(

GRFS

), down 3.8%,

Bristol-Myers Squibb Company

(

BMY

), down 2.0% and

HCA Holdings

(

HCA

), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Alere

(

ALR

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alere is up $7.30 (23.2%) to $38.77 on heavy volume. Thus far, 5.9 million shares of Alere exchanged hands as compared to its average daily volume of 888,900 shares. The stock has ranged in price between $35.76-$39.45 after having opened the day at $37.70 as compared to the previous trading day's close of $31.47.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Alere has a market cap of $3.8 billion and is part of the health services industry. Shares are down 19.5% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Alere a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Alere

as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full

Alere Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Jazz Pharmaceuticals

(

JAZZ

) is up $6.97 (4.9%) to $148.88 on heavy volume. Thus far, 2.8 million shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 803,800 shares. The stock has ranged in price between $136.00-$151.79 after having opened the day at $137.70 as compared to the previous trading day's close of $141.91.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $8.4 billion and is part of the drugs industry. Shares are up 1.0% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Jazz Pharmaceuticals

as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Jazz Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Alexion Pharmaceuticals

(

ALXN

) is up $2.19 (1.7%) to $131.97 on heavy volume. Thus far, 1.8 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $130.00-$135.00 after having opened the day at $134.00 as compared to the previous trading day's close of $129.78.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $28.4 billion and is part of the drugs industry. Shares are down 32.0% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Alexion Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).